UPDATE ON CHOCOLATE TOUCH® US PIVOTAL STUDY

Key Points:

- The clinical report with 12 months post-procedure analysis of the primary endpoints for Chocolate Touch® Pivotal Trial is expected to be the last major item required for FDA submission of a PMA application
- Marks significant step toward unlocking the post-closing payment from G Vascular of at least US$16.1 million for shareholders

SINGAPORE, 17 December 2021 – QT Vascular Ltd., (the "**Company**" or "**QT Vascular**", and together with its subsidiaries, the "**Group**"), is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease.

The Board of Directors ("**Board**") of the Company refers to its announcements dated 13 July 2020, 27 August 2020 and 30 August 2020 in relation to the proposed disposal of the Sale Asset which includes Chocolate Touch® Paclitaxel-Coated PTA Balloon Catheter by the Group to G Vascular Private Limited ("**G Vascular**").

The Company is pleased to announce that the Company's subsidiary, TriReme Medical, LLC ("**TML**"), has, under the terms of the definitive asset purchase agreement entered into with G Vascular announced on 27 August 2020, completed the analysis of 12-month post-procedure clinical data from the United States pivotal study of the Chocolate Touch® Paclitaxel-Coated PTA Balloon Catheter.

A randomized controlled trial evaluating the Company's Chocolate Touch® drug-coated balloon ("**DCB**") in symptomatic patients having femoro-popliteal arterial disease ("**Chocolate Touch® Pivotal Trial**" or "**Trial**") was conducted. The global, multicenter study originally planned to cover randomized patients 1:1 to receive either the Chocolate Touch® or the Lutonix® DCB (a DCB device commercialized by Becton, Dickinson and Company). The Chocolate Touch® Pivotal Trial's Co-Principal Investigators are Dr. Thomas Zeller of Universitaets-Herzzentrum Freiburg-Bad Krozingen, and Dr. Mehdi Shishehbor of University Hospitals Cleveland Medical Center.

The Chocolate Touch® Pivotal Trial was performed with the support of multiple professional parties to ensure the highest level of data. The Trial included clinical events committee and angiographic core laboratory managed by Yale University Cardiovascular Research Center, and an external ultrasound

core laboratory to assess clinical outcomes. The Trial's primary efficacy endpoint was true DCB success at 12 months post-procedure. The primary safety endpoint was freedom from major adverse events at 12 months post-procedure. A total of 313 patients were randomized to Chocolate Touch® (n=152) vs Lutonix DCB (n=161). TML is currently in the process of finalizing its submission to the United States Food and Drug Administration ("**FDA**") for pre-market approval ("**PMA**") of Chocolate Touch®. The submission to the FDA is expected later this month.

As at the date of this announcement, G Vascular has paid US$5.9 million (which comprised Closing Payment of US$4.9 million and assumed liabilities of US$1 million) to the Company and has made the necessary investment to progress the Trial and will continue to do so to obtain PMA approval from FDA for Chocolate Touch®. The completion of the analysis of the 12-month post-procedure clinical data of the Chocolate Touch® Pivotal Trial, which is expected to be the last major item required for FDA submission of a PMA, is a significant step towards unlocking the post-closing payment of at least US$16.1million from G Vascular, for the Company's shareholders as indicated in the Company's circular to shareholders in relation to the disposal of Chocolate Touch® to G Vascular dated 13 July 2020. The post-closing payment will be unlocked either upon sale of Chocolate Touch® asset to other parties or commercial sale of Chocolate Touch® after PMA of Chocolate Touch® has been received.

~~ End ~~

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company does not undertake any obligation to update publicly or revise any

forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.